

This report is made in order to comply with the Belgian Royal Decree of November 14, 2007. You can also find this information on the website of ThromboGenics (www.thrombogenics.com) under section Investor information.

ThromboGenics published its Interim Financial Report in Dutch. ThromboGenics has also an English translation of this Interim Financial Report. In case of differences of interpretation between the English and the Dutch versions of the Report, the original Dutch version has priority.

Interim Financial Report **Half-year results as of June 30, 2013**

Consolidated key figures as of June 30, 2013

Unaudited Consolidated statement of financial position

In '000 euro	30 June 2013	31 December 2012
Property, plant and equipment	3,681	2,699
Intangible assets	72,581	72,338
Goodwill	2,586	2,586
Other financial assets	1,738	1,724
Stocks	2,462	0
Other current assets	29,506	20,353
Cash and cash equivalents	185,669	139,398
Employee benefits	73	73
Total assets	298,296	239,171
Total equity	286,690	227,966
Current liabilities	11,606	11,205
Total equity and liabilities	298,296	239,171

Unaudited Consolidated statement of comprehensive income

In '000 euro	Half-year 2013	2012
Income	102,725	75,084
Operating result	54,076	55,285
Finance income	792	1,805
Finance expense	-259	-933
Result before income tax	54,609	56,157
Income tax expense	-1	-1
Net result for the period	54,608	56,156
Result per share		
Basic earnings per share (euro)	1.52	1.69
Diluted earnings per share (euro)	1.48	1.64

A full analysis of the interim financial statement, prepared in accordance to IAS 34 declared applicable by the European Union, is included under section “Condensed consolidated interim financial statements”. These statements were submitted to a limited review by the statutory auditor.

Business Highlights

JETREA® Highlights

JETREA® in the US

- **ThromboGenics launches the first and only pharmacological treatment for symptomatic VMA**

ThromboGenics launched JETREA®, the first and only treatment of symptomatic VMA in the US on 14 January 2013.

The FDA approval of JETREA® was based on ThromboGenics’ phase III data where the drug was shown to be superior to placebo for the treatment of symptomatic VMA. Treatment with JETREA® was associated with some, mainly transient, ocular adverse events.

Symptomatic VMA is a progressive condition that, if left untreated, frequently leads to retinal distortion, further deterioration in vision and has the potential to cause irreversible damage and complications. It is estimated that around 250,000 people in the US could benefit from treatment with JETREA®.

As with all progressive diseases, the introduction of a treatment option that could prevent the disease from progressing further could potentially be of great value to patients, physicians and payors alike. In the case of symptomatic VMA patients it could prevent them from experiencing deterioration in their visual acuity.

The introduction of JETREA® offers a treatment option for symptomatic VMA patients who previously remained largely untreated. Up until recently these patients underwent a period of watchful waiting prior to be treated surgically when their visual acuity had reached a point where surgical intervention, via vitrectomy, was needed.

The launch of a novel drug, such as JETREA®, for which there has previously been no or very limited treatment options, requires investment in medical education and time to establish a new treatment paradigm that involves changing well-established clinical practices.

- **Highly focused commercial organization working to educate the retina community and develop the sales of JETREA®**

ThromboGenics launched JETREA® in the US through its own highly focused commercial organization. The Company’s specialist sales force is working to convert the high level of awareness of JETREA® into the routine use of the product in clinical practice. The team is targeting the over 2,000 retinal physicians distributed across 1400 practices in the US who treat most of the patients presenting with symptomatic VMA.

Current sales of JETREA® reflect that it is a novel drug that has been approved for a new and broad indication which requires a change in treatment habits by physicians.

Since the product's launch in January, we have been successful in penetrating 51% of the clinical practices that we have been targeting and 62% of the practices have re-ordered JETREA®.

ThromboGenics' experience, supported by the results of an extensive market research survey conducted in July, indicate that the Company's medical education and marketing activities need to continue to focus on explaining the paradigm shift that JETREA® could deliver in the treatment of VMA..

The Company believes that JETREA® provides value both in moderate to severe patients and when it is used in mild to moderate patients in preference to the current approach which is to "watch and wait".

By using JETREA® in this way in mild to moderate patients, physicians have the opportunity to treat them before they experience deterioration in their visual acuity. At present, patients are only treated after their visual acuity has declined significantly, this being via a surgical procedure known as a vitrectomy.

Public and private reimbursement for JETREA® has been very favorable

ThromboGenics has applied for a permanent J-code which it expects to receive and take effect on January 1, 2014. A permanent J-code would be an important facilitator, as it will lead to the reimbursement process for JETREA® being automated and is expected to result in physicians being reimbursed in a more timely manner.

Our market research has indicated that the lack of a J-code has caused retina physicians to be more cautious in adopting JETREA® into their clinical practices.

ThromboGenics remains confident that further medical education and experience will allow US retina physicians to progressively integrate JETREA® into their clinical practice, leading to steady growth in the product's sales.

JETREA® in Europe and ROW

- **EU Approval for JETREA®**

In March, the European Commission approved JETREA® in the European Union for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. This decision by the European Commission applies to all 27 European Union Member states plus Iceland and Norway.

The EU approval of JETREA® triggered a €45 million milestone payment to ThromboGenics from its partner Alcon.

The EU approval of JETREA® followed the positive opinion on JETREA® in January 2013 from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

VMT, which in the US is referred to as symptomatic VMA, is an age-related progressive sight-threatening condition that may lead to visual distortion, decreased visual acuity and central blindness.

- **European Launches of JETREA®**

UK: In April, the Company announced that its partner Alcon had launched JETREA® in the UK, its first market in Europe. The first sale of JETREA® by Alcon triggered a further €45 million milestone payment to ThromboGenics.

JETREA® is currently undergoing a single technology appraisal (STA) by the National Institute for Health and Care Excellence (NICE) as part of the process to gain reimbursement when used by the UK National Health Service.

On August 30 upcoming, NICE will issue its Final Appraisal Determination (FAD) regarding the reimbursement of JETREA® by the UK's National Health Service.

NICE made a positive preliminary recommendation by NICE in its Appraisal Consultation Document in June. The outcome of the STA, in the form of NICE guidance, is expected in the final quarter of 2013.

Germany: In May, Alcon launched JETREA® in both the public and private healthcare markets in Germany, the second European market where the product is now available. As of 1 May 2013, JETREA® has been listed in the "Lauer-Taxe" (Große Deutsche Spezialitätentaxe) with an ex-factory price of €3,078.

In August, Germany's IQWiG, an independent federal organization that evaluates a drug's quality and efficiency, confirmed that JETREA® (ocriplasmin) demonstrates major/significant added value compared with existing comparative treatment, when treating mild/moderate vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns.

IQWiG's recommendation is made to the Federal Joint Committee (G-BA), which issues final guidance on a drug's benefit assessment. G-BA final guidance on JETREA® is expected in mid-October 2013.

Nordic region: In May and June, ThromboGenics launched JETREA® in Denmark, Sweden, Finland and Norway.

Canadian Approval

JETREA® received approval in Canada for the treatment of symptomatic vitreomacular adhesion (VMA). This represents the first approval of JETREA® outside the US and Europe. Alcon is expected to launch the drug in Canada shortly.

Promising data with JETREA® in patients with wet AMD

In May 2013, ThromboGenics reported promising data from a Phase IIa study evaluating JETREA® in treating vitreomacular adhesions associated with wet age-related macular degeneration (AMD).

The Phase IIa study was a multi-center randomized, sham-injection controlled, double masked trial of ocriplasmin intravitreal injection for the treatment of vitreomacular adhesion in patients with wet AMD. The trial recruited a total of 100 patients, of which 75 patients were randomized to receive a single intravitreal injection of ocriplasmin. Patients were recruited at centers across the United States and Europe

In the trial, 24% of the wet AMD patients treated with JETREA® saw complete resolution of their VMA at Day 28 compared to only 12% of patients who received a sham injection. This small study did not meet its primary statistical end point ($p=0.26$). Both groups of patients received concomitant anti-VEGF treatment.

This is the first time a controlled study with JETREA® has shown that it may resolve the vitreomacular adhesions observed in wet AMD patients, a potential new patient population. Wet AMD is a significant retinal disorder and these data warrant further studies to confirm the clinical benefits that JETREA® may provide to patients with wet AMD. ThromboGenics is currently discussing the future development plans for JETREA® in this important indication with Alcon.

The full data (primary and secondary endpoints) of this Phase IIa study will be presented at the Annual American Academy of Ophthalmology (AAO) meeting in New Orleans
(*Ocriplasmin In Exudative AMD: Results of A Prospective Randomized Clinical Trial by Roger L Novack MD PhD* - November 16, 2013)

Other Pipeline Products

- **TB-403 – Novel Mode of Action in medulloblastoma published in *Cell***

In February, the Company announced the publication of a paper in the prestigious journal *Cell* highlighting the potential of TB-403 (anti-PIGF) to improve the treatment of medulloblastoma, the most common brain tumor in children.

The *Cell* publication highlights for the first time a new mechanism of action, showing that PIGF plays a vital role in the brain and that its expression is required for the growth and spread of medulloblastoma.

The novel positive findings in this paper provide evidence that could warrant further development of TB-403 as one of the first targeted therapies to treat this childhood cancer. TB-403 is a monoclonal antibody against placental growth factor (PIGF). PIGF is a naturally occurring protein that belongs to the family of vascular endothelial growth factors (VEGF) that promote the formation of blood vessels.

Expanding our ophthalmology franchise

- **ThromboGenics to develop novel protein therapeutics for diabetic eye diseases using Eleven Biotherapeutics' technology**

In May, ThromboGenics announced the start of a collaborative research project to develop innovative protein therapeutics to address a novel biologic target implicated in a range of diabetic eye diseases such as diabetic macular edema.

ThromboGenics will utilize Eleven Biotherapeutics' proprietary AMP-Rx protein design technology to create a novel therapeutic chosen by ThromboGenics and optimized for improved pharmaceutical characteristics and projected therapeutic benefits.

ThromboGenics will have the exclusive license to all future developments and commercialization of this novel protein. In exchange, Eleven Biotherapeutics will receive an undisclosed upfront payment, and is eligible to receive undisclosed development, regulatory and sales milestone payments as well as royalties on potential future sales commensurate with industry standards.

- **ThromboGenics supports new KU Leuven Chair**

ThromboGenics announced in May that it is supporting a new Research Chair “ThromboGenics Chair in Pharmacological and Surgical Vitrectomy” at KU Leuven (University of Leuven), in Leuven, Belgium.

The funding of the Chair is intended to advance fundamental research. Its holder is appointed by the Rector of the university on the recommendation of the Dean of the relevant faculty. The holder may use the funding for teaching or research.

The Chair, established jointly by ThromboGenics and KU Leuven, is intended to further research and evaluate effects of vitreous removal with the goal of treating serious retinal diseases such as symptomatic vitreous adhesion (VMA) / vitreous traction (VMT). The chair will be held by Prof. Dr. Peter Stalmans, Department of Ophthalmology, University Hospitals Leuven, Belgium. ThromboGenics will provide financial support to cover the Chair’s teaching and/or research expenses. ThromboGenics is committed to funding the Chair for a period of three years.

Condensed consolidated interim financial statements

Unaudited consolidated statement of comprehensive income

In '000 euro	Half - year	
	2013	2012
Income	102,725	75,084
Sales	12,519	0
License income	90,000	75,036
Income from royalties	206	37
Other income	0	11
Cost of sales	-3,878	-3,145
Gross profit	98,846	71,939
Research and development expenses	-18,135	-10,431
General and administrative expenses	-7,010	-4,237
Selling expenses	-20,438	-4,367
Other operating income	813	2,381
Operating result	54,076	55,285
Finance income	792	1,805
Finance expense	-259	-933
Result before income tax	54,609	56,157
Income tax expense	-1	-1
Net result for the period	54,608	56,156
Attributable to:		
Equity holders of the company	54,608	56,156
Result per Share		
Basic earnings per share (euro)	1.52	1.69
Diluted earnings per share (euro)	1.48	1.64

Unaudited consolidated statements of other comprehensive income

In '000 euro	Half - year	
	2013	2012
Result of the period	54,608	56,156
Revaluation of available-for-sales financial assets	55	0
Exchange differences on translation of foreign operations	217	-254
Other comprehensive income, net of income tax	272	-254
Total comprehensive income for the period	54,880	55,902
Attributable to:		
Equity holders of the company	54,880	55,902

Unaudited consolidated statement of financial position

In '000 euro	30 June 2013	31 December 2012
ASSETS		
Property, plant and equipment	3,681	2,699
Intangible assets	72,581	72,338
Goodwill	2,586	2,586
Other financial assets	1,738	1,724
Employee benefits	73	73
Non-current assets	80,659	79,420
Stocks	2,462	0
Trade and other receivables	21,625	11,520
Investments	7,881	8,833
Cash and cash equivalents	185,669	139,398
Current assets	217,637	159,751
Total assets	298,296	239,171
EQUITY AND LIABILITIES		
Share capital	151,991	150,938
Share premium	157,662	155,754
Accumulated translation differences	-111	-328
Other reserves	-14,267	-15,205
Retained earnings	-8,585	-63,193
Equity attributable to equity holders of the company	286,690	227,966
Minority interests		
Total equity	286,690	227,966
Trade payables	9,598	9,303
Other short-term liabilities	2,008	1,902
Current liabilities	11,606	11,205
Total equity and liabilities	298,296	239,171

Unaudited consolidated statement of cash flows

In '000 euro	Half - year	
	2013	2012
Cash flows from operating activities		
(Loss) profit for the period	54,608	56,156
Finance expense	259	933
Finance income	-792	-1,806
Depreciation on property, plant and equipment	539	278
Depreciation on intangible assets	3,079	0
Equity settled share-based payment transactions	883	0
Change in trade and other receivables including tax receivables and stock	-12,567	-863
Change in short-term liabilities	400	-3,011
Net cash (used) from operating activities	46,409	51,687
Cash flows from investing activities		
Disposal of property, plant and equipment	15	2
Change in investments	1,007	14,008
Interest received and similar income	659	867
Acquisition of intangible assets	-3,322	-22,320
Acquisition of property, plant and equipment	-1,535	-775
Acquisition of other financial assets	-14	-2
Net cash (used in) generated by investing activities	-3,190	-8,220
Cash flows from financing activities		
Proceeds from issue of share capital	2,960	76,484
Paid interests	-5	-4
Net cash (used in) generated by financing activities	2,955	76,480
Net change in cash and cash equivalents	46,174	119,947
Cash and cash equivalents at the start of the period	139,398	57,548
Effect of exchange rate fluctuations	96	-245
Cash and cash equivalents at the end of the period	185,669	177,250

Unaudited consolidated statement of changes in equity

	Share capital	Share premium	Cumulative translation differences	Other reserves	Retained earnings	Attributable to equity holders of the company	Minority interests	Total
Balance as at 1 January 2012	138,351	91,165	-633	-17,246	-93,608	118,029	0	118,029
Net result 2012					56,156	56,156		56,156
Change to foreign currency translation difference			-254			-254		-254
Conversion of warrants by ThromboGenics NV	549	835				1,384		1,384
Issue of ordinary shares	11,827	63,273				75,100		75,100
Balance as at 30 June 2012	150,727	155,273	-887	-17,246	-37,452	250,415	0	250,415
Balance as at 1 January 2013	150,938	155,754	-328	-15,205	-63,193	227,966	0	227,967
Net result 2013					54,608	54,608		54,608
Change to foreign currency translation difference			217			217		217
Net change in fair value of investments				55		55		55
Conversion of warrants by ThromboGenics NV	1,053	1,908				2,961		2,961
Issue of ordinary shares								0
Share-based payment transactions				883		883		883
Balance as at 30 June 2013	151,991	157,662	-111	-14,267	-8,585	286,690	0	286,690

Notes to the condensed consolidated interim financial statements

1. General information

ThromboGenics NV (“the Company”) was incorporated on May 30, 2006, and is a limited liability company (in Dutch: naamloze vennootschap). The registered office is established at:

Gaston Geenslaan 1
3001 Leuven
Belgium
Tel: +32 (0)16 751 310
Fax: +32 (0)16 751 311

The company is registered in the Crossroads Databank for Enterprises under single business number 0881.620.924.

ThromboGenics is listed on Euronext Brussels. ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the treatment of eye diseases. The Company’s lead product is JETREA[®] which was granted approval by the US Food and Drugs Administration (FDA) on October 18, 2012, for the treatment of symptomatic vitreomacular adhesion (VMA), otherwise indicated as vitreomacular traction (VMT). On January 14, 2013, JETREA[®] was launched in the US. Therefore ThromboGenics has developed its own sales and marketing team.

On March 15, 2013, the European approval of the European Commission followed.

In March 2012, ThromboGenics signed a strategic partnership deal with Alcon (Novartis) for the commercialization of JETREA[®] outside the US. This agreement provides that, ThromboGenics will receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon’s net sales of JETREA[®]. Under this agreement ThromboGenics, already received €75 million in 2012 and €90 million in 2013.

These condensed interim consolidated financial statements of ThromboGenics for the six months ended June 30, 2013 (the ‘Interim period’) include ThromboGenics NV and its subsidiary ThromboGenics Inc. and constitute the ThromboGenics Group. These statements were approved by the Board of Directors on August 29, 2013. These statements were submitted to a limited review by the statutory auditor.

The consolidated financial statements of the Group for the year 2012 are available upon request on the above mentioned address or on the internet (www.thrombogenics.com/investor-information/reports-and-presentations/)

2. Summary of significant accounting policies

2.1. Basis of preparation of half-year report

This condensed consolidated interim financial information has been prepared in accordance with IAS 34, (Interim Financial Reporting) as adopted by the European Union.

The condensed consolidated interim financial information does not include all the necessary information for drawing up financial statements of a full accounting year and therefore should be read in conjunction with the annual financial statements of the group for the year ended December 31, 2012.

Drawing up the condensed consolidated interim financial statements in accordance with IFRS obliges the management to make estimates and assumptions that affect the reported amounts of assets, liabilities and the notes on the latent assets and liabilities on the date of the condensed consolidated interim financial statements, and the reported amounts of income and costs during the reporting period. If in the future such estimates and assumptions, which are based on management's best estimates and judgment, deviate from the actual circumstances, the original estimates and assumptions will be modified and the effects of the revisions will be reflected in the period in which the circumstances change. The principal risks during the interim period have not materially changed from those mentioned in the financial report as of December 31, 2012.

All statements and information relate to the interim period unless otherwise stated.

The consolidated financial statements are presented in euro and all values are rounded to the nearest thousand except when otherwise indicated.

2.2. Accounting policies

The same accounting policies, presentation and methods of computation have been followed in these condensed financial statements as were applied in the preparation of the Group's financial statements for the year ended December 31, 2012, except for the potential impact of the adoption of the Standards and Interpretations described below.

New Standards, Interpretations and Amendments adopted by the Group

During the current financial year, the Group has adopted all the new and revised Standards and Interpretations issued by the International Accounting Standards Board (IASB) and the International Financial Reporting Interpretations Committee (IFRIC) of the IASB, that are relevant to its operations and effective for the accounting year starting on January 1, 2013. The Group has not applied any new IFRS requirements that are not yet effective as per June 30, 2013.

The following new Standards, Interpretations and Amendments issued by the IASB and the IFRIC are effective for the current period:

Annual Improvements to IFRSs 2009-2011 Cycle (issued by the IASB in May 2012)

IFRS 1 - First-time Adoption of International Financial Reporting Standards (Amendment March 2012)
— Amendments for government loan with a below-market rate of interest when transitioning to IFRSs

IFRS 7 - Financial Instruments: Disclosures (Amendment December 2011) — Amendments related to the offsetting of assets and liabilities

IFRS 10 - Consolidated Financial Statements – Original Issue May 2011

IFRS 10 - Consolidated Financial Statements (Amendment June 2012) – Amendments to transitional guidance

IFRS 11 - Joint Arrangements - Original Issue May 2011

IFRS 11 - Joint Arrangements (Amendment June 2012) – Amendments to transitional guidance

IFRS 12 - Disclosure of Interests in Other Entities - Original Issue May 2011

IFRS 12 - Disclosure of Interests in Other Entities (Amendment June 2012) – Amendments to transitional guidance

IFRS 13 - Fair Value Measurement - Original Issue May 2011

IAS 1 Presentation of Financial Statements (Amendment June 2011) — Amendments to revise the way other comprehensive income is presented

IAS 19 - Employee Benefits (Amendment June 2011) — Amended Standard resulting from the Post-Employment Benefits and Termination Benefits projects

IAS 27 - Consolidated and Separate Financial Statements — Reissued as IAS 27 Separate Financial Statements (May 2011)

IAS 28 - Investments in Associates — Reissued as IAS 28 Investments in Associates and Joint Ventures (May 2011)

IFRIC 20 - Stripping Cost in the Production Phase of Surface Mine

The adoption of this amendment has not led to major changes in the Group's accounting policies.

Standards and Interpretations issued but not yet effective in the current period

The Group elected not to early adopt the following new Standards, Interpretations and Amendments, which have been issued but are not yet effective as per June 30, 2013.

IFRS 7 - Financial Instruments: Disclosures (Amendment December 2011) — Deferral of mandatory effective date of IFRS 9 and amendments to transition disclosures

IFRS 9 - Financial Instruments — Classification and Measurement (Original issue November 2009)

IFRS 9 - Financial Instruments — Reissue to include requirements for the classification and measurement of financial liabilities and incorporate existing derecognition requirements (October 2010)

IFRS 9 - Financial Instruments (Amendment December 2011) — Deferral of mandatory effective date of IFRS 9 and amendments to transition disclosures

IFRS 10 - Consolidated Financial Statements (Amendment October 2012) – Amendments for investment entities

IFRS 12 - Disclosure of Interests in Other Entities (Amendment October 2012) – Amendments for investment entities

IAS 27 - Consolidated and Separate Financial Statements (Amendment October 2012) — Amendments for investment entities

IAS 32 - Financial Instruments: Presentation (Amendment December 2011) — Amendments relating to the offsetting of assets and liabilities

IAS 36 – Impairment of Assets (Amendment May 2013) — Recoverable Amounts Disclosures for Non-Financial Assets

IAS 39 – Financial Instruments: Recognition and Measurement (Amendment June 2013) — Novation of Derivatives and Continuation of Hedge Accounting

IFRIC 21 – Levies (May 2013)

2.3. Exchange rates

During the Interim period, the Group is mainly confronted with transactions in euro, US Dollar (USD) and Pound Sterling (GBP). The exchange rate between euro and USD was on average €1.3134 and on period ending €1.3080. The exchange rate between euro and GBP was on average €0.8508 and on period ending €0.8572.

3. Segment information

On this interim financial report, no segment information was reported. The Group does not have a reporting per company, and the decisions of the management are based on the figures of the Group.

4. Seasonality of operations

The activities of research and development within ThromboGenics are not in any way seasonal.

5. Group structure and important events and transactions

The consolidated interim financial statements include ThromboGenics NV and its subsidiary ThromboGenics Inc., US.

During the interim period, there were no important changes to the group structure as mentioned in the financial statement for the fiscal year which was closed as of December 31, 2012.

6. Result of the period

During the first six months of 2013, the income of ThromboGenics amounted to €102.7 million, this includes €12.5 million of sales, of which €12.4 million of product sales in the US and €0.1 million of products recharged to Alcon, and an upfront payment of €90 million from Alcon. This compares to a total income of €75.1 million in the first six months of 2012, which mainly came from an upfront payment of Alcon.

During the first six months of 2013, the Group had a gross profit of €98.9 million.

ThromboGenics' R&D expenses were €18.1 million during the first half year, including a first depreciation on the intangible fixed assets with regards to Phase III of €3.1million, versus €10.4 million in the same period of 2012.

In the first half of 2013, selling and marketing expenses amounted to €20.4 million compared with €4.4 million in the corresponding period of 2012. This increase reflects the growth of the Company's commercial organization due to the launch of JETREA®.

ThromboGenics achieved a net financial income of €0.5 million in the first half of 2013.

ThromboGenics reported a net profit of €54.6 million for the first half of 2013 (€1.52 per share) compared to €56,2 million net profit in the same period of 2012 (€1.69 per share).

7. Financial position and cash flow

As of June 30, 2013, ThromboGenics had €193.6 million in cash and cash equivalents (including €7.9 million investments). This compares to €186.1 million on June 30, 2012 (including €8.8 million investments) and €148.2 million on December 31, 2012 (including €8.8 million investments).

ThromboGenics current cash resources will allow the Company to execute its operational projects.

At the end of the first half-year of 2013, the total equity of ThromboGenics was €286.7 million versus €228.0 million at the end of 2012.

8. Capital structure and evolution of the equity

On June 30, 2013, there were 36,094,349 ordinary shares versus 35,860,224 on December 31, 2012. The increase is the result of a capital increase by a contribution in cash and 234,125 warrants being exercised.

The share capital and the issue premium evolved as a result of the transactions listed above as follows:

In '000 euro	Capital	Issue premium
31 December 2012	150,938	155,754
Capital increase – exercising warrants April 2013	1,053	1,908
30 June 2013	151,991	157,662

The profit of the period was carried forward and brings the equity at €286.7 million on June 30, 2013.

The results were approved by the Board of Directors on 29 August 2013. The Board of Directors is responsible for the preparation and presentation of the condensed consolidated financial information.

9. Key agreements, commitments and contingent liabilities

Interest bearing loans and financial instruments

The Group has not concluded any new credit agreements during the interim period, nor any new financial instruments.

Litigation

The Group has no material pending litigation.

Other Commitments

The company has not concluded any new commitments that could influence substantially the financial position of the Company.

For the risks and the uncertainties for the rest of the year, we refer to the analysis included in the latest available Annual Report for 2012. No new elements have occurred in the first six months of 2013, which should require a modification of the list of risks and uncertainties.

10. Transactions with Related parties

In the first 6 months of 2013, an amount of €3,210 thousand was paid to LSRP vzw as a royalty obligation. This amount was based on the €90 million upfront payment, ThromboGenics received from Alcon.

Further €2,1 million was paid to the executive directors.

No other transactions with related parties were made which have a material impact on the financial position and results of the Group. There were also no changes to related party transactions disclosed in the Annual Report 2012 that potentially had a material impact to the financials of the first 6 months of 2013.

11. Events occurring after the reporting period

The German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA[®] (ocriplasmin) demonstrates major/significant added value in VMT patients with mild/moderately severe symptoms compared with existing comparative treatment, when treating vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns.

On August 16, 2013, ThromboGenics announces that Health Canada has approved JETREA[®] (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). Canada is the first market where JETREA[®] is approved outside the US and Europe. Alcon holds the commercialization rights to JETREA[®] outside the US and will be responsible for the launch of the drug in Canada.

On September 16, 2013 at 4:00 PM, an extraordinary shareholders' meeting which will be held at the office of associated notaries Celis, Celis & Liesse, Antwerp, Kasteelpleinstraat 59, with the following most important point on the agenda: approval of a new warrant plan, named Warrant Plan 2013: issuance of 720,000 new warrants, each giving right to one share under the conditions and modalities mentioned in the Warrant Plan 2013.

Furthermore, no significant events have occurred after the balance sheet date that may have an impact on the presentation of the interim financial statement submitted.

12. Impairment

At the end of every reporting period, management judges the possible presence of indications which can lead to the necessary booking of impairments.

During the first six months of 2013, no such indications were found.

Declaration of responsible persons

Chris Buyse, Chief Financial Officer of ThromboGenics declares that, as far as he is aware:

- The condensed consolidated interim financial statements, made up according to the applicable standards for financial statements, give a true and fair view of the equity, financial position and the results of the Company and its consolidated companies.
- This interim report represents a true and fair view of the development and the results of the company for the first 6 months of 2013, and of the principal risks and uncertainties for the second half year and of the transactions with related parties.

Statutory auditor's report to the Board of Directors of ThromboGenics NV on the limited review of consolidated interim financial information for the six-month period ended 30 June 2013

Introduction

We have reviewed the accompanying interim consolidated statement of financial position of ThromboGenics NV as of 30 June 2013 and the related interim consolidated statements of comprehensive income, cash flows and changes in equity for the six-month period then ended, as well as the explanatory notes. The Board of Directors is responsible for the preparation and presentation of this consolidated interim financial information in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union.

Zaventem, 29 August 2013

BDO Bedrijfsrevisoren Burg. Ven. CBVA / BDO Réviseurs d'Entreprises Soc. Civ. SCRL
Statutory auditor
Represented by Bert Kegels